Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Top 10: Die beste Smartwatch im Test – Apple Watch schlägt Samsung, Xiaomi & Co. (Heise) +++ SAMSUNG VZ Aktie -3,54%

PFIZER Aktie

 >PFIZER Aktienkurs 
25.065 EUR    -2.0%    (TradegateBSX)
Ask: 25.07 EUR / 4800 Stück
Bid: 25.05 EUR / 4800 Stück
Tagesumsatz: 95978 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
PFIZER Aktie über LYNX handeln
>PFIZER Performance
1 Woche: -3,9%
1 Monat: -2,8%
3 Monate: +8,3%
6 Monate: +17,6%
1 Jahr: +16,2%
laufendes Jahr: +20,1%
>PFIZER Aktie
Name:  PFIZER INC. DL-,05
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7170811035 / 852009
Symbol/ Ticker:  PFE (Frankfurt) / PFE (NYSE)
Kürzel:  FRA:PFE, ETR:PFE, PFE:GR, NYSE:PFE
Index:  S&P500
Profil:  Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare di..
>Volltext..
Marktkapitalisierung:  149611.44 Mio. EUR
Unternehmenswert:  192599.76 Mio. EUR
Umsatz:  57867.21 Mio. EUR
EBITDA:  20929.51 Mio. EUR
Nettogewinn:  3667.12 Mio. EUR
Gewinn je Aktie:  0.64 EUR
Schulden:  56999.55 Mio. EUR
Liquide Mittel:  1658.94 Mio. EUR
Operativer Cashflow:  12891.31 Mio. EUR
Bargeldquote:  0.45
Umsatzwachstum:  4.97%
Gewinnwachstum:  -57.37%
Dividende je Aktie:  1.49 EUR
Dividendenrendite:  5.96%
Dividendenschätzung:  5.94%
Div. Historie:  06.11.26 - 0.38583902€
24.07.26 - 0.378013€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  PFIZER
Letzte Datenerhebung:  19.11.26
>PFIZER Kennzahlen
Aktien/ Unternehmen:
Aktien: 5699.85 Mio. St.
Frei handelbar: 99.91%
Rückkaufquote: -
Mitarbeiter: 75000
Umsatz/Mitarb.: 0.76 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 5.2%
Bewertung:
KGV: 41.81
KGV lG: 9.29
KUV: 2.61
KBV: 1.87
PEG-Ratio: -
EV/EBITDA: 9.2
Rentabilität:
Bruttomarge: 65.1%
Gewinnmarge: 6.34%
Operative Marge: 25.95%
Managementeffizenz:
Gesamtkaprendite: 1.95%
Eigenkaprendite: 4.44%
 >PFIZER Anleihen 
>PFIZER Peer Group
 
19.11.26 - 18:15
Can New Products and Acquisitions Revive Pfizer′s Growth Story? (Zacks)
 
PFE's new launches and acquisitions are reshaping its business, supporting its ambitions to return to growth from 2029....
19.11.26 - 10:48
Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here′s What It Would Take to Break the Streak. (Fool)
 
Pfizer's dividend streak spans 88 years, and it would take a perfect storm to end it....
18.11.26 - 13:54
Pfizer Licenses Autoimmune Disease Programs From Starna In Deal Worth Upto $2.63 Bln (AFX)
 
NEW YORK CITY (dpa-AFX) - Drugmaker Pfizer Inc. (PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics for three prec......
18.11.26 - 13:21
Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.11.26 - 20:24
Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5% (24/7 Wall St.)
 
Income investors tend to crowd into whatever is popular, leaving solid payers ignored. The three stocks below are in health care, telecom, and financials. Each pays at least 5%, and each has price or valuation data showing the market has lost interest. Take Pfizer (NYSE: PFE), whose share price is still 26.37% below where it […]...
17.11.26 - 19:36
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue (Fool)
 
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters....
17.11.26 - 10:54
Pfizer auf der Jefferies Healthcare Conference: Pipeline-Offensive, KI und Sparprogramm gegen die Patentklippe (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
16.11.26 - 17:06
5 Ultra-High-Yield Dividend Stocks Retirees Should Buy Before December (24/7 Wall St.)
 
Retirees heading into December want income they can count on, and this list holds five dividend payers from five sectors that report solid cash coverage behind the payouts. Three of them, Verizon Communications (NYSE:VZ), MPLX (NYSE:MPLX) and Ares Capital (NASDAQ:ARCC), clear the 6% bar for ultra-high-yield status. Pfizer (NYSE:PFE) and Omega Healthcare Investors (NYSE:OHI) sit […]...
16.11.26 - 12:00
The Zacks Analyst Blog Highlights Visa, ExxonMobil Holdings and Pfizer (Zacks)
 
Visa, ExxonMobil Holdings and Pfizer are included in this Analyst Blog....
14.11.26 - 18:24
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027? (Fool)
 
Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors....
14.11.26 - 10:48
Pfizer′s 5.9% Yield vs. AbbVie′s 53-Year Dividend Streak: Which Stock Is the Better Buy? (Fool)
 
These healthcare dividend stocks appeal to investors in different ways....
14.11.26 - 00:15
Top Stock Reports for Visa, ExxonMobil & Pfizer (Zacks)
 
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), ExxonMobil Holdings Corporation (XOM) and Pfizer Inc. (PFE)....
13.11.26 - 20:24
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now? (Fool)
 
Pfizer isn't out of the woods yet, but it is proving it remains a well-run drugmaker....
13.11.26 - 17:48
Pfizer Is Up 15.78% This Year, but $1,000 From Five Years Ago Is Still Worth Just $704 With Dividends Reinvested (24/7 Wall St.)
 
Pfizer (NYSE:PFE) closed at $28.83 on Nov. 12, 2026, up 15.78% from its $24.90 close on Dec. 31, 2025. A $1,000 purchase at the Nov. 30, 2021 month-end close of $53.73 is worth $704, including reinvested dividends, a -29.6% change. On share price alone, the five-year change is -46.3%. Both numbers trace back to the […]...
13.11.26 - 16:45
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit? (Zacks)
 
PFE shares fell despite the company beating Q3 estimates and raising guidance. Explore its growth drivers, pipeline potential, patent risks & attractive valuation....
13.11.26 - 15:18
A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer (24/7 Wall St.)
 
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders....
12.11.26 - 21:12
Pfizer offshoot Zoetis lines up ′potential blockbuster′ pet meds for Japan (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
12.11.26 - 17:33
"Not Just Going To Be Oversight": Dems Line Up Probes Of Ex-Chief Of Staff Susie Wiles (ZeroHedge)
 
"Not Just Going To Be Oversight": Dems Line Up Probes Of Ex-Chief Of Staff Susie Wiles Authored by Aldgra Fredly via The Epoch Times,Rep. Robert Garcia (D-Calif.) said on Nov. 10 that former White House chief of staff Susie Wiles could face a congressional probe once Democrats take over Congress next year.Garcia was responding to a reporter's question about whether the House Oversight Committee would investigate allegations that Wiles lobbied for interest groups during her tenure as chief of staff.As we reported on Nov. 10, the accusations come from former Kennedy aide Calley Means, who told Joe Rogan that Wiles said "I need the sugar industry money," and pollster Mark Mitchell, who said Wiles warned him off criticizing Pfizer. A Wiles spokesperson called the accusations "outrageous, defamatory, and provably false," and Ballard Partners, her former lobbying firm, says it has never represented Pfizer."We've already been looking at Susie Wiles. With all of this new information that's come out...
12.11.26 - 16:48
Blackstone Is Paying Up to $1.5 Billion for Pfizer′s Answer to Wegovy (24/7 Wall St.)
 
Pfizer just convinced Wall Street's biggest private investor to shoulder its obesity bet, yet the payoff for shareholders may not come from the drug at all. The real story sits in who keeps the upside and what arrives first....
12.11.26 - 06:18
Pfizer, Blackstone Strike Up To $1.5 Bln Co-Funding Deal To Develop Obesity Drug Berobenatide (AFX)
 
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Blackstone Life Sciences announced a strategic co-funding agreement under which Blackstone-managed funds will pay Pfizer up to $1.5 billion in devel......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Geld liebt, wird nie genug davon haben. - Salomo
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!